Table 1 Demographic and clinical data
From: Sertraline treatment influences [18F]FE-PE2I PET imaging for Parkinsonism
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Modafinil patient | |
|---|---|---|---|---|---|
Gender | Female | Female | Female | Male | Male |
Age | 58 | 74 | 78 | 76 | 65 |
Daily sertraline intake (mg) | 100 | 100 | 125 | 50 | 100 (Modafinil) |
Time of daily sertraline intake | Evening | Evening | Morning | Evening | – |
Symptoms suggesting Parkinsonism | Action tremor, rigidity and dysdiadochokinesia | Initially treated for essential benign tremor, but no effect of treatment, and now action tremor as well | Fall, gait disturbances, hallucinations and cognitive decline | Cognitive decline, gait disturbances, apathetic, fall and urine incontinence | Unilateral tremor, slow movements, obstipation, hyposmia and reduced balance |
CT/MRI findings | Sequelae in relation to previous infarction in the right hemisphere | Leukoaraiosis (Fazekas gr I/II) | Enlarged ventricular system and leukoaraiosis (Fazekas gr III) | Pronounced atrophy, leukoaraiosis and sequelae in relation to previous lacunar infarction | Light frontal atrophy and leukoaraiosis (Fazekas gr I/II) |
Comorbidities | Diabetes type II, depression, hypertension and hypothyroidism | Previous gastric cancer (radical surgery), cirrhosis, polyarthritis and knee arthrosis | Hypertension, rheumatoid arthritis, osteoporosis and hip fracture | Diabetes type II, hypertension, diverticulosis and fever of unknown origin | Periodic depression, prostate cancer, cataract and dilation of aorta ascendens |
Other medication | Promethazine, levothyroxine, dapagliflozin, metformin, atorvastatin, ezetimibe, clopidogrel and enalapril | Colchicine, spironolactone, pramipexole and clopidogrel | Methotrexate, bisphosphonates, prednisolone and clopidogrel | Enalapril, insulin glargine, atorvastatin, prednisolone, semaglutide, ezetimibe, dapagliflozin, clopidogrel and metformin | Modafinil, citalopram, zolpidem and lithium citrate |